Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krebs Biochemicals and Industries Limited published its audited financial results for Q4 and FY2026 in newspapers on May 22, 2026. For FY2026, total income was Rs 4,402.08 lakhs, up from Rs 2,575.79 lakhs in FY2025. However, the company reported a net loss of Rs 2,693.93 lakhs for FY2026, significantly worse than the Rs 1,693.31 lakh loss in FY2025. Loss per share worsened to Rs 12.49 in FY2026 from Rs 7.85 in FY2025. Q4 FY2026 showed total income of Rs 881.27 lakhs with a net loss of Rs 233.96 lakhs. The company continues to operate at a loss despite increased revenue.
The stock is likely to face selling pressure as the company reports significantly widened losses for FY2026. Revenue growth did not translate into profitability, suggesting ongoing operational or financial challenges. Shareholders should monitor turnaround efforts.